Hiroyuki Marusawa

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium

Yuko Matsumoto, Hiroyuki Marusawa, Kazuo Kinoshita et al. · Nature Medicine · 2007 · 471 citations

Life Sciences, Microbiology, Molecular Biology +14

The bioenergetic signature of cancer: a marker of tumor progression.

José M. Cuezva, Maryla Krajewska, Miguel López de Heredia et al. · PubMed · 2002 · 439 citations

Life Sciences, Cell Biology, Oncology +17

HBXIP functions as a cofactor of survivin in apoptosis suppression

Hiroyuki Marusawa, Shu‐ichi Matsuzawa, Kate Welsh et al. · The EMBO Journal · 2003 · 434 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12